BIO-TECHNE Corp 4
4 · BIO-TECHNE Corp · Filed Sep 12, 2016
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
Gould Kevin S
SVP Clinical Controls
Transactions
- Sale
Common Stock
2016-09-08$110.50/sh−524$57,904→ 1,667 total
Holdings
- 50,000
Stock Options (Right to Buy)
Exercise: $97.23Exp: 2022-07-09→ Common Stock (50,000 underlying) - 17,371
Stock Options (Right to Buy)
Exercise: $106.59Exp: 2023-08-18→ Common Stock (17,371 underlying) - 2,111
Restricted Stock Units
→ Common Stock (2,111 underlying) - 10,000
Stock Options (Right to Buy)
Exercise: $88.23Exp: 2023-01-04→ Common Stock (10,000 underlying) - 13,028
Stock Options (Right to Buy)
Exercise: $106.59Exp: 2023-08-18→ Common Stock (13,028 underlying) - 15,000
Stock Options (Right to Buy)
Exercise: $97.23Exp: 2022-07-09→ Common Stock (15,000 underlying)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.4934 to $110.5402 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Includes 833 shares of restricted stock units that vest on 7/9/17 and 834 shares of restricted stock units that vest on 7/9/18.
- [F3]50,000 common stock options vest if certain performance goals are achieved for the 12 months ending 05/31/18.
- [F4]Vests as to 2,500 shares on each of 01/04/17, 01/04/18, 01/04/19 and 01/04/20.
- [F5]Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20.
- [F6]Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- [F7]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.